Announcement Summary

Entity name

AUSTRALIAN CLINICAL LABS LIMITED

Announcement Type

New announcement

Date of this announcement

22/3/2023

The Proposed issue is:

Total number of +securities proposed to be issued for a placement or other type of issue

| ASX +security code | +Security description | Maximum Number of +securities to be issued |
|--------------------|-----------------------|---|
| ACL | ORDINARY FULLY PAID | 450,830,889 |

Proposed +issue date

6/10/2023

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

AUSTRALIAN CLINICAL LABS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

Registration Number

ABN

94645711128

1.3 ASX issuer code

ACL

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

22/3/2023

1.6 The Proposed issue is:

A placement or other type of issue

Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1a Conditions

Approval/Condition
Other (please specify in comment section)

Date for determination

21/9/2023

Is the date estimated or actual?

** Approval received/condition met?

Comments

ACL's off-market takeover bid for Healius Limited (ACN 064 530 516)(Healius)(Offer) is subject to the conditions stated in section 11.9 of ACL's bidder statement dated 20 March 2023 being satisfied or waived by ACL. The date for giving notice of the conditions is 21 September 2023 (subject to variation if the Offer is extended).

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

☑ No

Details of +securities proposed to be issued

ASX +security code and description

ACL: ORDINARY FULLY PAID

Number of +securities proposed to be issued

450,830,889

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

⊘ No

Please describe the consideration being provided for the +securities

Under the Offer, eligible Healius shareholders will be entitled to receive 0.74 ACL shares in consideration for every Healius share held (fractional entitlements rounded down to the next whole number of ACL shares). See ACL's bidder statement dated 20 March 2023 for further details.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

✓ Yes

Part 7C - Timetable

7C.1 Proposed +issue date

6/10/2023

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
☑ Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

19/9/2023

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

⊗ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

⊗ No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

⊗ No

7E.2 Is the proposed issue to be underwritten? ⊗ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Please refer to section 10.6 of ACL's bidder's statement dated 20 March 2023

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

As consideration for the transfer of Healius shares to ACL under the Offer on the terms and conditions outlined in ACL's bidder's statement dated 20 March 2023.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? ⊗ No

7F.2 Any other information the entity wishes to provide about the proposed issue

Refer to ACL's bidder's statement dated 20 March 2023 for further information regarding the Offer. The proposed issue date in this Appendix 3B is dependent on the outcome of the Offer (including the fulfilment or waiver of the Offer conditions) and timing of acceptances under the Offer. The number of ACL shares that are proposed to be issued in this Appendix 3B is subject to the assumptions set out in section 5.2 of ACL's bidder's statement dated 20 March 2023

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

☑ The publication of a +disclosure document or +PDS for the +securities proposed to be issued